Blocking the IL-8/CXCR2/HK2 axis effectively reduces PD-L1 expression and lactate production, enhancing the impact of anti-PD-1 therapy for advanced gastric cancer, with potential clinical benefits. Here, CXCL8 is linked to gastric cancer.